Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer

Inclusion Criteria: 1. Histologically or cytologically confirmed, previously untreated and surgically resectable non-small cell lung cancer (stage II-IIIA, patients with squamous cell carcinoma or EGFR mutation should not be included); 2. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 3. Satisfactory preoperative laboratory testing and adequate pulmonary function for surgery; 4. Patients approve and sign the informed consent. Exclusion Criteria: 1. Pancoast tumor, squamous cell carcinoma, large-cell carcinoma and sarcomatoid carcinoma; 2. Patients with active autoimmune disease or history of autoimmune disease; 3. Patients who have a condition requiring systemic treatment with either prednisone or other immunosuppressive medications; 4. Patients with a history of symptomatic interstitial lung disease; 5. History of allergy to study drug components; 6. Women must not be pregnant or breast-feeding; 7. Men with female partners that are not willing to use contraception; 8. Patients who have received prior chemotherapy, anti-angiogenesis therapy and immunotherapy for this malignancy or for any other past malignancy; 9. Patients who have received prior treatment for non-small cell lung cancer; 10. Any mental or psychological condition which would not permit the patient to complete the study or understand the patient information; 11. Patients who have major hemoptysis within the past 4 weeks, tumor has invasion or is close to great vessels; 12. Patients with high risk of major bleeding; 13. Patients who have arterial thrombotic events, esophageal varices, peptic ulcers, wounds or bone fractures; 14. Patients who have prior malignancies; 15. HIV, HBV, HCV infection or active pulmonary tuberculosis; 16. Underlying medical conditions that, in the Investigator's opinion, will make the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events.